Komori
Other Disclosures4884Kringle Pharma,Inc.Pharmaceuticals

Notice Regarding Participation in Reeve Summit 2026

A representative of our US subsidiary will participate in an international summit on spinal cord injury to be held in Boston, US, from 6–8 May 2026. We will sponsor the summit as a Silver Sponsor.

Worth reading
56In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Announced details

Recombinant human HGF protein (International Nonproprietary Name: oremepermin alpha)
Applicable field (uses covered by this announcement)

Spinal cord injury, patient support, and spinal cord injury treatment development

Launch date6 May 2026 (scheduled; the first day of the summit)
Relationship between the counterparty and the company
Kringle Pharma,Inc.4884
Relationship with the Company

We will sponsor Reeve Summit 2026 as a Silver Sponsor, and the President of our US subsidiary will participate.

CounterpartyChristopher & Dana Reeve Foundation

A US-based nonprofit organization that promotes research into treatments for paralysis, including spinal cord injury, and works to improve the quality of life of people living with paralysis and their families.

Location (as indicated in this announcement)

Boston, US (summit venue)

In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.

Source (materials cited by the company)

National Spinal Cord Injury Statistical Center『Traumatic Spinal Cord Injury Facts and Figures at a Glance, 2026』

Announced details
ItemDetails
Names of Products / Services CoveredRecombinant human HGF protein (International Nonproprietary Name: oremepermin alpha)
CounterpartyChristopher & Dana Reeve Foundation
Counterparty overviewA US-based nonprofit organization that promotes research into treatments for paralysis, including spinal cord injury, and works to improve the quality of life of people living with paralysis and their families.
Relationship with the CompanyWe will sponsor Reeve Summit 2026 as a Silver Sponsor, and the President of our US subsidiary will participate.
Launch date6 May 2026 (scheduled; the first day of the summit)
Applicable areaSpinal cord injury, patient support, and spinal cord injury treatment development
LocationBoston, US (summit venue)
SourceNational Spinal Cord Injury Statistical Center『Traumatic Spinal Cord Injury Facts and Figures at a Glance, 2026』
Items this document does not state (10)
Contract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocation scaleQuantitative EffectsUsage historyImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To obtain patient-perspective information from patients and their families, researchers, support organizations and others, deepen our understanding of unmet needs, and reflect this in our global development strategy, including in the US.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding Participation in Reeve Summit 2026 | Kringle Pharma,Inc. (4884) timely disclosure | Komori